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Abstract: The prevalence of diabetic polyneuropathy (DPN) can approach 50% in subjects with 
longer-duration diabetes. The most common neuropathies are generalized symmetrical chronic 
sensorimotor polyneuropathy and autonomic neuropathy. It is important to recognize that 50% of 
subjects with DPN may have no symptoms and only careful clinical examination may reveal the 
diagnosis. DPN, especially painful diabetic peripheral neuropathy, is associated with poor quality of 
life. Although there is a better understanding of the pathophysiology of DPN and the mechanisms of 
pain, treatment remains challenging and is limited by variable efficacy and side effects of therapies. 
Intensification of glycemic control remains the cornerstone for the prevention or delay of DPN but 
optimization of other traditional cardiovascular risk factors may also be of benefit. The manage-
ment of DPN relies on its early recognition and needs to be individually based on comorbidities and 
tolerability to medications. To date, most pharmacological strategies focus upon symptom control. 
In the management of pain, tricyclic antidepressants, selective serotonin noradrenaline reuptake 
inhibitors, and anticonvulsants alone or in combination are current first-line therapies followed by 
use of opiates. Topical agents may offer symptomatic relief in some patients. Disease-modifying 
agents are still in development and to date, antioxidant α-lipoic acid has shown the most promising 
effect. Further development and testing of therapies based upon improved understanding of the 
complex pathophysiology of this common and disabling complication is urgently required.
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Introduction
Diabetes is the most common cause of neuropathy leading to significant morbidity 
and is associated with increased mortality.1 Prevalence approaches 50% for people 
with long-established diabetes. Presentation, in the early stages, can comprise sym-
metrical, painful neuropathy involving the lower limbs, which can predate the diag-
nosis of diabetes. Paradoxically in later stages, pain can still be present with disabling 
symptoms, yet on clinical examination there is loss of sensation, so-called “painful 
painless neuropathy”. Poor glycemic control leads to progression of DPN and many 
studies have shown that intensification of metabolic control can slow or halt disease 
progression. Currently available disease-modifying treatments have not been effec-
tive in reversing the pathological process and present therapies are targeted, therefore, 
more towards pain relief.
Definition
DPN is defined as the presence of symptoms and/or signs in the peripheral nerves, pre-
dominantly affecting the lower extremities in the absence of other causes of   neuropathy. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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The San Antonio Consensus Statement on Diabetic   Neuropathy 
defined the condition as being a “demonstrable disorder, either 
clinically evident or subclinical in the setting of diabetes 
  without other causes of peripheral neuropathy”.2
Epidemiology
The epidemiology and the natural history of DPN are difficult 
to define, reflecting the inconsistencies of clinical diagnostic 
criteria, variable selection of patients, and wide-ranging 
physiological techniques. The EURODIAB Complications 
Study identified a prevalence of 28% for DPN at baseline, 
with glycemic control and duration of diabetes being major 
determinants; similar findings were observed in subjects in 
the Diabetes Control and Complications Trial (DCCT).2 In a 
cohort of 4400 Belgian patients, the prevalence was estimated 
to be about 7.5% in newly diagnosed diabetes, increasing to 
45% after 25 years of diabetes.3 In the United Kingdom, the 
prevalence of DPN among a hospital clinic population was 
around 29%.4 The prevalence is estimated to be 10% to 18% 
in newly diagnosed type 2 diabetes based on nerve electro-
physiological studies, reflecting that “mild” disturbances of 
the glucose milieu can lead to nerve   damage.5 The enhanced 
sensitivity of nerves to glucotoxicity is supported by the 
presence of symptomatic neuropathies in individuals who 
were found to have impaired glucose tolerance (IGT) which 
typically affects small nerve fibers based on measurements 
of intra-epidermal nerve fiber density (IENFD).6 In the 
Augsburg surveys, the prevalence of DPN based on Michigan 
Neuropathy Screening Instrument was 13.0% in those with 
IGT, 11.3% in those with impaired fasting glucose (IFG), 
and 7.4% in those with normal glucose tolerance (NGT) vs 
28.0% in subjects with established diabetes (P = 0.05 for 
diabetes vs NGT, IFG, and IGT).7
The reported prevalence of painful DPN typically ranges 
from 10%–26% based on differing criteria used to diagnose 
neuropathic pain.8 In a European multicenter study of 1171 
diabetic patients, the prevalence of painful DPN in subjects 
with type 1 and type 2 diabetes was 11.6% vs 32.1% respec-
tively in the lower limbs and 7.1% vs 16.6% in the upper 
limbs. In newly diagnosed type 2 subjects, the prevalence has 
been reported to be 6% increasing to 20% at 10 years.9
Risk factors for DPN  
and neuropathic pain
The risk factors for the development of DPN were analyzed 
in the EURODIAB Prospective Complications Study of 
1100 people with type 1 diabetes followed over a period 
of 7.3 years. Risk factors appeared to be similar to the 
factors for macrovascular disease, such as hypertension, 
smoking, elevated HbA1c, increased lipid levels, duration of 
diabetes, and body mass index (Figure 1).10 In the Augsburg 
surveys, age, waist circumference, and diabetes were shown 
to be independent risk factors for the developing neuropathic 
pain. The presence of peripheral arterial disease was a 
significant contributor to neuropathic pain both in diabetic 
and nondiabetic subjects. This is an important factor to be 
considered in the diagnosis and treatment of neuropathic   
pain.11
Symptoms and signs
The classification of diabetic neuropathies is complex 
reflecting the diverse etiology, pathology, the heterogeneous 
nature of symptoms, varied clinical course, and pattern of 
neurological involvement (Table 1). DPN can be broadly 
divided as suggested by Thomas et al12,13 and Boulton et al14,15 
into generalized polyneuropathies and focal and multifocal 
varieties. Recently the Toronto Diabetic Neuropathy Expert 
Group suggested a further division of the generalized vari-
eties into two subgroups of typical and atypical reflecting 
differences of onset, course, clinical manifestations, associa-
tions, and pathophysiology.16   Furthermore, minimal criteria 
were suggested for typical DPN (into categories of possible, 
probable, confirmed, and subclinical) based upon abnormali-
ties of symptoms and signs and nerve electrophysiology. 
According to these criteria, the presence of an abnormality 
of nerve conduction in addition to a symptom(s) or a sign(s) 
is necessary for confirmation. However in the presence of 
normal electrophysiology, a validated measure of small fiber 
neuropathy (Figure 2) could be utilized.16
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Figure 1 eURODiAB: risk factors for incidence of polyneuropathy.
Notes: excluding cardiovascular disease and retinopathy. Odds ratios (95% Ci); 
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Table 1 Classification of diabetic polyneuropathies
A. Generalized symmetrical polyneuropathy
 •  Chronic sensorimotor polyneuropathy
  ◊ Small fiber neuropathy
  ◊ Large fiber neuropathy
  ◊ Mixed
 •  Acute sensory neuropathy
  ◊ Hyperglycemic neuropathy
  ◊ “Cachetic” neuropathy
 •  “Peripheral”autonomic neuropathy
  ◊ Sudomotor neuropathy
  ◊ “Autosympathectomy”
B. Focal neuropathy
 •  Cranial neuropathy
 •  Focal-limb neuropathy
C. Multifocal neuropathies
 •  Radiculoplexus neuropathies
  ◊ Lumbar polyradiculopathy (diabetic amyotrophy)
  ◊ Lumbo-sacral polyradiculopathy
  ◊ Thoracic polyradiculopathy
Generalized polyneuropathy
Diabetic sensorimotor polyneuropathy
Diabetic sensorimotor polyneuropathy (DSPN) is perhaps 
the most common form of DPN. It is a chronic, symmetrical 
neuropathy, which typically begins in the toes and gradually 
and insidiously ascends to involve the lower legs. Lesions 
or dysfunction of small myelinated and unmyelinated 
nerve fibers and larger myelinated nerve fibers occur in 
varying combinations; however, in most cases, the earliest 
deficits involve small nerve fibers. The features of small 
fiber neuropathy can include paresthesias and dyesthesia, 
hyperalgesia, burning, or lancinating pain and deficits in 
pain and temperature perception. Sensory symptoms can 
be mild; occasional tingling or pins and needles (paresthe-
sia) or more disabling in terms of burning or stabbing with 
symptoms tending to be worse at night. The most frequent 
location of pain has been reported to be as follows: 96% 
feet, 69% balls of feet, 67% toes, 54% dorsum of foot, 39% 
hands, 37% plantum of foot, 37% calves, and 32% heels.17 
In extreme cases, patients may experience hypoalgesia and 
allodynia when even the lightest of touch can provoke per-
ception of severe pain. The precise prevalence of allodynia 
in DPN is however controversial. Unpleasant sensations of 
lancinating or “electric-shock” nature can result from small 
fiber involvement. Negative symptoms of numbness and 
hypoalgesia are also commonly reported within the presenta-
tion of sensorimotor polyneuropathy. Large myelinated fiber 
involvement leads to loss of vibration, touch, and position 
perception with decreased or absent ankle reflexes. Severe 
impairment of proprioception can lead to sensory ataxia and 
denervation-mediated wasting of small intrinsic muscles of 
the feet and hands, which can lead to weakness and deformity 
and occurs late in the disease process.12,18–21 The duration of 
pain varies with complete to partial remission possible if a 
precipitating event can be identified.22 Shorter pain duration 
(ie, ,6 months), in general, has a better prognosis.
It is generally proposed that chronic hyperglycemia 
with resultant downstream metabolic derangements in 
concert with cardiovascular risk factors23 leads to impaired 
microvascular perfusion which is the fundamental deficit in 
pathogenesis of DSPN and is often found in association with 
other long-term microvascular complications.16,23
Acute sensory neuropathy
Rarely, the symptoms of DPN are acute with severe inten-
sity of pain associated with sudden and extreme weight 
loss. This has been associated with depression and erectile 
dysfunction. Electrophysiological evidence of neuropathy 
may be mild or absent consistent with predominant involve-
ment of small nerve fibers. Symptoms may subside in 
,1 year and weight loss responds well to insulin therapy.24 
Similar findings may be observed in girls with anorexia 
and diabetes,24 which can portend a troublesome future of 
rapidly progressive DPN.
Similarly, the so-called rapidly reversible hyperglycemic 
neuropathy, which occurs in patients with recently diagnosed 
or poorly controlled diabetes, usually presents with distal 
sensory symptoms that are unlikely to be associated with 
structural nerve abnormalities and recover following restora-
tion of euglycemia.16
Acute painful neuropathy which develops after improve-
ment of glycemic control, so-called “insulin neuritis”, has 
been described as “non-length-dependent” in that the distal 
extremities are not necessarily the most severely affected.25,26 
This topographic distribution of neuropathy has also been 
described in subjects with impaired glucose tolerance.27 
Symptoms usually respond to conventional treatments for 
neuropathic pain within 1 year.
Autonomic polyneuropathies
In diabetic neuropathy, innervation of peripheral vascula-
ture is decreased or absent. Loss of sympathetic tone in the 
blood vessels results in vasodilation leading to arteriovenous 
shunting. The “warm” neuropathic feet due to arteriovenous 
shunting can be associated with the distension of foot veins 
that fail to collapse even when the foot is elevated and 
can result in edema, which is resistant to diuretics. The Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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increased blood flow in the feet has been postulated to cause 
osteopenia and is associated with the development of Charcot 
  neuroathropathy.28 The oxygen tension of the blood in these 
veins is typically raised.
Peripheral sudomotor neuropathy can affect the feet with 
loss of sweating, resulting in dry skin with fissures predispos-
ing to the risk of infection.29 The term “autosympathectomy” 
has been used to describe the occurrence of peripheral vaso-
motor instability and peripheral sudomotor neuropathy. Sweat 
glands are innervated by sudomotor, postganglionic, thin, 
unmyelinated cholinergic sympathetic C-fibers. C-fibers also 
contribute to microvascular blood flow regulation. C-fiber 
dysfunction can occur early in the course of DPN.
Several methods have been developed to assess sudomo-
tor function with variable degree of complexity and accu-
racy including thermoregulatory sweat testing, quantitative 
sudomotor axon reflex test sympathetic skin response, and 
quantitative direct and indirect axon reflex testing, silicone 
impressions, and the indicator plaster. The indicator plaster 
has been developed as a simple tool to detect the presence 
of DPN.30
Measurement of IENFD is also becoming widely 
accepted as an important highly reproducible31,32 tool for 
the quantitative assessment of the presence and severity of 
small sensory fiber loss. Intra-epidermal nerve fibers are the 
most distal processes of small myelinated and unmyelinated 
axons. These fibers can be quantified utilizing a minimally 
invasive technique of skin punch biopsy31 (Figure 2). 
  Normative ranges have been reported31 which demonstrate 
that the density of epidermal nerve fibers decreases with 
age and is lower in men than in women.32 IENFD has been 
found to correlate with the severity of neuropathy34,35 as 
measured using sural nerve small myelinated fiber density,35 
thermal thresholds,33,36,37 vibration perception threshold, and 
electrophysiology.33,36
Small sensory nerve fiber loss in the cornea can also 
be assessed using the technique of corneal confocal 
microscopy.16,33 This technique has been shown to correlate 
with loss of IENFs and with the severity of neuropathy in 
patients with diabetes.33 It appears to be a highly sensi-
tive measure by which to measure a therapeutic effect 
of disease-modifying interventions since it was reported 
to improve 6 months following pancreatic and kidney 
transplantation.38
Focal and multifocal neuropathies
Different mechanisms such as mild, repeated mechanical 
trauma, compression and entrapment, ischemia, and inflam-
matory process have been invoked in the development of 
focal and multifocal neuropathies,39–41 which differ from 
typical DSPN in that they may occur early as well as later in 
the course of diabetes.
Mononeuropathy is common in both type 2 and type 1 
diabetes. Cranial neuropathy, which perhaps results from 
inflammation, microvasculitis, and/or ischemia is rare and 
commonly affects the nerves that supply the extraocular 
muscles, especially oculomotor, abducens, and trochlear. 
Patients with diabetic opthalmoplegia present with unilateral 
pain, ptosis, and diplopia with sparing of pupillary reaction. 
Though these neuropathies are similar to those observed in 
nondiabetic subjects, Bell’s palsy occurs more frequently 
in diabetic than nondiabetic patients. Mechanical insult 
is likely to contribute to carpal tunnel syndrome which 
results from median nerve entrapment at the wrist (median 
mononeuropathy) or foot drop secondary to peroneal nerve 
involvement at the fibular head. Median mononeuropathy can 
be asymptomatic and can lead onto wasting and weakness 
of hand grip.42
Radiculo-plexus neuropathies
Lumbosacral plexus-radiculo-neuropathy involve the L2, L3, 
and L4 roots and is often described as diabetic amyotrophy.16 
Typically, older patients in the fifth to sixth decades of life 
with type 2 diabetes present with thigh pain followed by 
muscle weakness in one leg and sensory loss at the level of 
the lumbar plexus or lumbar roots and femoral nerve. The 
knee jerk reflex is usually reduced or absent on the affected 
side with preservation of ankle jerk unless affected by distal 
polyneuropathy. The symptoms may have monophasic or 
stepwise progression and are usually accompanied by weight 
loss. The condition tends to resolve over 6 months to 1 year. 
The diagnosis is made on history and clinical examination 
and electromyographic studies. The etiology may be an 
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immune mediated vasculitis with ischemia since there is 
evidence of immune complex and complement deposition in 
nerve and muscle biopsy. Limited data suggest that treatment 
with intravenous immunoglobulins, prednisolone, and/or 
plasma exchange may result in fewer long-term neurologi-
cal sequelae.43–45 It is important to achieve good metabolic 
control in all cases.
Diabetic truncal radiculoneuropathy tends to affect 
middle-aged to elderly male patients. It is less common 
than lumbosacral plexus-radiculo-neuropathy but causes 
marked symptoms with a girdle-like distribution pain over 
the lower thoracic or abdominal wall. It may be uni- or 
bilaterally distributed and resolution generally occurs within 
4–6 months.
Pathophysiology
The development of DPN is multifactorial. The metabolic 
effects of chronic hyperglycemia and the consequences of 
ischemia on the peripheral nerves are likely to be the two 
fundamental mechanisms leading to neuro-axonal dysfunc-
tion and damage.
In sensorimotor polyneuropathy, the pathophysiologi-
cal effects of hyperglycemia are wide ranging and include 
activation of polyol pathway, generation of reactive oxygen 
species (ROS) (oxidative stress) and reactive nitrogen species 
(nitrosative stress), and accumulation of advanced glycation 
end products (AGE)46 (Figure 3). Excess glucose flux through 
the polyol or sorbitol pathway is reduced to sorbitol by the 
enzyme aldose reductase, a rate limiting step in this pathway, 
before being oxidized by sorbitol dehydrogenase to fructose, 
a potent glycating agent. The intracellular accumulation of 
sorbitol leads to reduction in nerve myoinositol and taurine 
and disruption of Na+/K+-ATPase membrane activity, leading 
to nerve sodium accumulation, impaired axonal transport and 
structural damage to the nerves.
Hyperglycemia accelerates the glycation of free amino 
group on proteins, lipids, and nucleic acids with alteration 
in their molecular structure and functions.47 The base-
ment membrane of endothelial cells becomes glycosylated 
thereby contributing to impaired vasodilation. There is also 
excess formation and accumulation of AGEs due to reduced 
clearance of these macromolecules. Additionally, AGEs 
bind to receptors of AGE on macrophages with production 
of inflammatory cytokines (interleukin-1, tumor necro-
sis factor-α), growth factors (insulin like growth factor, 
platelet derived growth factor, tissue growth factor-β) and 
adhesion molecules (vascular cell adhesion molecules-1) 
(VCAM-1).48–54
Elevated intracellular glucose also stimulates formation 
of diacylglycerol, which leads to the activation of protein 
kinase C (PKC).53,54 The role of PKC is better defined in the 
pathogenesis of diabetic retinopathy and although the mecha-
nism of its involvement in neuronal damage is unclear and 
debated, it probably is mediated via an effect on endothelial 
cell function.
A common final endpoint for many pathogenic pathways 
is impaired nerve perfusion, hypoxia, and nerve energetic 
defects. The multiple mechanisms cited above can result 
in overproduction of ROS, especially superoxide anion by 
the mitochondrial electron transport chain. The availability 
of endothelial nitric oxide (NO) is reduced as superoxide 
binds to NO to form the strong oxidant peroxynitrite which 
is directly toxic to endothelial cells.56–59 Endothelial cells 
elaborate NO, a potent vasodilator, which antagonizes 
thrombosis, has anti-inflammatory properties, is important 
in cell signaling, and can inhibit growth of vascular smooth 
muscle cells.56–62 NO also inhibits the production of the potent 
vasoconstrictor peptide endothelin (ET)-1. Other agents 
involved in mediating the vasodilatation of microcircula-
tion include substance P and calcitonin gene related peptide 
(CGRP), in addition to bradykinin, histamine, and vasoactive 
intestinal polypeptide there is impaired dilator response to 
these peptides in diabetes.55–58 Therefore, diabetes results in 
an imbalance of vasoactive agents, with the ultimate effect 
of impaired microvascular perfusion.
Another novel pathway, which has been implicated in the 
pathogenesis of the complications of diabetes, is activation 
of nuclear enzyme poly (ADP ribose) polymerase (PARP). 
Increased oxidative stress results in DNA damage and 
PARP 1 activation, which can lead to cellular energy fail-
ure, which is thought to be important in the pathogenesis of 
DPN.63 Diabetic rodent models administered PARP inhibitors 
or deficient in the PARP gene demonstrate protection against 
the development of experimental DPN. These models also 
demonstrate reduced levels of epineurial vessel superoxide 
and nitrotyrosine, suggesting that the relationship between 
oxidative stress and PARP may be bidirectional rather than 
unidirectional.63 For a detailed review of the role of oxidative 
stress in the pathogenesis of DPN, the reader is referred to 
Figueroa-Romero et al.56
Mechanism of neuropathic pain
Overall the mechanisms that contribute to the development of 
pain in diabetes are poorly understood but probably involve 
deficits at multiple levels from the skin nociceptors to the 
pain processing areas of the brain.16 It is also important to Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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consider the impact of cultural influences on the perception 
of pain, since the experience of pain complicating diabetes 
differs across ethnic groups which cannot be explained on the 
basis of clinical findings. The pain pathway starts from the 
periphery with nociceptor activation and transmission through 
the small unmyelinated C fibers and the larger myelinated 
A-δ fibers and A–β fibers. The major neurotransmitter in C 
fibers is glutamate and its release is regulated through calcium 
channels. Glutamate in turn excites postsynaptic N-methyl-
D-aspartate (NMDA) receptors resulting in the release 
of substance P in the substantia gelatinosa, an important 
neurotransmitter of pain perception. The descending fibers 
modulate the response to pain via serotonergic, opioidergic, 
and α-2-adrenergic pathways.64 The A-β the A-δ fibers 
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Figure 3 Pathophysiology of microvascular injury.
Abbreviations: ACe, angiotensin converting enzyme; AGe, glycation end products; AR, aldose reductase; DAG, diacylglycerol; PARP, poly (ADP ribose) polymerase; PKC, 
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transmit pain perception by depolarization, which is mediated 
by sodium channels, of which sodium channels 1.7 and 
1.8 play an important role in pain signaling via glutamate. 
This excites an interneuron with release of γ-aminobutyric 
acid (GABA), which further   modulates pain sensation.65,66 
Interestingly, a number of   studies suggest that loss of IENFs 
is related to the development of pain in a variety of chronic 
disease states. For example, subjects with painful diabetic 
neuropathy have been shown to exhibit a significant reduc-
tion of IENFD compared with diabetic patients with painless 
neuropathy.67
The definition of neuropathic pain (NP) as proposed by 
International Association of Study of Pain “pain initiated or 
caused by a primary lesion or dysfunction in the nervous 
system” has limitations as it overlooks the plasticity of the 
nervous system and its continuous modulation, which may 
change after activation or injury.68 The word “dysfunction” 
in the definition of NP allows the inclusion of organic pain 
states that do not have identifiable lesions of any part of the 
nervous system or an initiating neural injury. The revised 
definition proposed by Treede et al, based on consensus state-
ment defines NP as “pain arising as a direct consequence of 
a lesion or disease affecting the somatosensory system”.68 
Peripheral NP and central NP refer to lesions/disease of 
the peripheral nervous system and central nervous system, 
respectively.
Treatment of diabetic 
polyneuropathy
Treatment of DPN can be viewed as approaches aimed at 
modifying the disease process or strategies aimed at the 
alleviation of symptoms. Often the primary aim is to protect 
the lower limbs from damage due to sensory loss or to relieve 
pain, thus improving physical well-being and reducing psy-
chological distress in order to enhance the quality of life.
Disease-modifying treatment
Glycemic control
The pathogenesis of DPN is fundamentally mediated by 
hyperglycemia and/or insulin deficiency and their associated 
downstream actions. Indeed, glycemic control appears to be 
the most effective treatment to slow the progression of dia-
betic neuropathy and delay its onset. In the DCCT, intensive 
metabolic control with insulin resulted in a 60% reduction 
in clinical and electrophysiological evidence of neuropathy 
compared to standard care over a period of 5 years in sub-
jects with type 1 diabetes.69,70 In patients with early diabetes, 
intensive glycemic control significantly attenuates neuropathy 
  progression.70 Furthermore, the beneficial effect of intensive 
glycemic control applied early in the course of diabetes 
appears to have long-lasting effects (metabolic memory).71 
However, the DCCT gave little evidence that established 
neuropathy could be reversed by intensive insulin therapy. In 
the Epidemiology of Diabetes Intervention and Complication 
Trial (EDIC Trial), 64% of the original cohort from DCCT 
were followed up for 16 years. The incidence of diabetic neu-
ropathy remained lower in subjects previously randomized to 
intensive treatment after 5 years despite the lack of difference 
in HbA1c. The term “imprinting” of metabolic memory or 
“legacy” effect has been coined to describe this effect.71
Limited information exists with regards to the effects of 
glycemic control on pain. Boulton et al demonstrated that 
greater mean glucose excursions are associated with higher 
neuropathic pain scores and that use of continuous subcutane-
ous insulin infusion resulted in significant improvement in 
pain scores. These studies were, however, limited to a small 
number of patients.72,73
In the (UK Prospective Diabetes Study) UKPDS, in newly 
diagnosed type 2 diabetes, intensive treatment with sulfonylu-
rea, metformin, and insulin, which resulted in a 0.9% reduction 
in HbA1c after 10 years compared to conventional treatment, 
led to 25% reduction in microvascular endpoints, especially 
in retinopathy progression and albuminuria.74,75 However, 
absent ankle reflexes, taken as a sign of diabetic neuropathy 
were noted in 35% and 37% of intensively and conventionally 
treated subjects respectively, suggesting limited impact on this 
endpoint. In the Steno-2 trial, which assessed the efficacy of 
multifactorial risk   factor intervention, improvements in glyce-
mic control, lipid profile, and blood pressure were associated 
with a reduction in the odds ratio to 0.32 for the development 
of autonomic neuropathy.76 Intensification of metabolic control 
did not affect the progression of DPN, but may have reflected 
the limited assessment of DPN performed in this study (limited 
to a biothesiometer assessment).
α-lipoic acid
As discussed above, there is considerable evidence for an 
important role for neurovascular dysfunction in the patho-
genesis of DPN related to the downstream effects of free 
radical-mediated oxidative stress. D-L-α-lipoic acid (ALA) 
is a potent antioxidant, which has been extensively evaluated 
in prospective, placebo-controlled studies in subjects with 
diabetic neuropathy. A meta-analysis of 1258 patients who 
were treated with infusions of ALA (600 mg intravenously/
day) concluded that neuropathic symptoms and deficit were 
reduced after 3 weeks of treatment.77,78Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Initial studies with ALA showed limited benefit 
in symptom scores with some improvement in nerve 
  electrophysiology. In the (Alpha-Lipoic Acid in Diabetic 
Neuropathy) ALADIN II trial, subjects with type 1 and type 
2 diabetes complicated by symptomatic polyneuropathy were 
randomly assigned for 2 years to 1200 mg, or 600 mg ALA 
or placebo after intravenous infusion of ALA or placebo. 
The severity of diabetic neuropathy was assessed by the 
neuropathy disability score and electrophysiological studies. 
No significant differences between the groups were detected 
after 24 months apart from dose-dependent improvement in 
electrophysiological nerve function. In the ALADIN III trial, 
there was a small but significant improvement in neuropathy 
impairment score in patients treated with ALA.79,80
However, in the Symptomatic Diabetic Neuropathy 
(SYDNEY) 1 trial, ALA intravenously given for 3 weeks was 
associated with improvement of symptoms. In SYDNEY 2 
trial, three doses of oral ALA (600, 1200, or 1800 mg daily) 
or placebo were randomly assigned to 181 diabetes patients 
with symptomatic polyneuropathy for 5 weeks. All three 
doses were associated with significant improvement in the 
neuropathy total symptom score compared to placebo.81,82
The benefit and safety of ALA has been demonstrated in a 
long-term study, NATHAN, which was a multicenter, random-
ized, double-masked, parallel group clinical trial involving 
460 diabetic patients with polyneuropathy randomly assigned 
to receive ALA 600 mg or placebo. After 4 years, ALA was 
shown to be well tolerated and to improve neuropathic symp-
toms and deficits compared to a progression of these endpoints 
in the placebo arm.83 ALA has been licensed and is currently 
used in treatment of symptomatic diabetic neuropathy in 
Germany. A dose of 600 mg/day appears to offer the best 
balance between efficacy and side effect profile.
Protein kinase C
Activation of PKC is thought to be an important pathogenetic 
pathway in diabetic microvascular complications. In the 
multinational, randomized, Phase II double-blind placebo-
controlled trial using ruboxistaurin (a PKC-β inhibitor) there 
was, however, no difference in the primary endpoint of change 
in vibration detection threshold (VDT). For the secondary 
endpoint, there was improvement in the neuropathy total 
symptom score 6 (NTSS 6). Patients who had significant 
symptoms at baseline did show a statistically significant 
change in symptoms with 64 mg dose but not with a 32 mg 
dose compared to the placebo. In a subgroup analysis of 
patients with clinically significant symptoms and less severe 
DPN, there was significant greater reduction in NTSS 6 total 
score with the 64 mg dose (P = 0.006 vs placebo) and an 
improvement in the VDT.84,85
Polyol pathway
Aldose reductor inhibitors (ARIs) reduce the flux of glucose 
through the polyol or sorbitol pathway, resulting in the reduc-
tion of intracellular accumulation of sorbitol and fructose. In 
a 52-week, multicenter, placebo-controlled, double-blind trial, 
the use of fidarestat in patients with type 1 and type 2 diabetes 
with peripheral neuropathy was associated with significant 
improvement in five out of the eight electrophysiological 
measures over the course of the study with no deterioration 
from baseline in the treated group. At the study conclusion, 
the fidarestat-treated group improved significantly compared 
with the placebo group in two of the electrophysiological 
measures. There was also subjective symptomatic improve-
ment in the treated group.86 The ARI epalrestat is approved in 
Japan for clinical use. The clinical efficacy has been assessed 
in a 3-year, open-label, randomized control trial (RCT) of 594 
DPN subjects. One hundred and fifty mg/day of epalrestat was 
found to result in improvement in patients’ symptoms and 
prevented the deterioration of median motor nerve conduction 
velocity and minimum F wave latency.87
Another ARI that has been evaluated in a Phase III study is 
ranirestat. 549 patients with DPN were randomized to   placebo 
or 10, 20, or 40 mg/day of ranirestat for 52 weeks. There 
was no change in the Toronto clinical neuropathy score and 
quantitative sensory testing among the groups. There were 
nonsignificant changes in sural and sensory nerve conduc-
tion but significant improvement in summed motor nerve 
conduction velocity of tibial, peroneal, and median nerves 
in the ranirestat group by 12 weeks.88 Currently, the focus 
has changed from reversing established disease to slowing 
the progression of neuropathy and a prospective clinical trial 
with ranirestat is underway to address this.
Advanced glycation end  
products
The accumulation of AGEs and activation of AGE receptors 
results in multiple downstream pathogenetic effects leading 
to microvascular damage. However the identification and 
testing of a safe AGE inhibitor has proved problematic. The 
inhibition of AGE formation, amino-guanidine, was discon-
tinued because of toxicity in humans.89
Benfotiamine, a derivative of thiamine (vitamin B1), has 
been shown to reduce tissue AGEs. Studies of benfotiamine in 
subjects with DPN with varying doses and duration have been 
reported to show some effectiveness compared to placebo. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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A 6-week, placebo-controlled study with benfotiamine 300 mg 
or 600 mg demonstrated a reduction in neuropathic symptoms, 
which was optimal at the higher dose. Benfotiamine has also 
been studied in combination with pyridoxamine (vitamin B6) 
and cyanocobalamin (vitamin B12). These studies reported 
a significant improvement in vibration perception threshold, 
motor function, and symptom score.90,91
Growth factors
There is evidence for deficient neurotrophism in diabetes. 
However prospective clinical trials utilizing nerve growth factor 
(NGF) and neurotropin 3 did not show promising results.92,93 
Another growth factor, vascular endothelial growth factor 
(VEGF), which is an important stimulus for angiogenesis, has 
been studied in animal models of diabetic neuropathy as well as 
in clinical trials in patients with diabetes.94,95 VEGF was shown to 
improve symptoms without effecting nerve   electrophysiology.94 
Islet neogenesis associated protein, a pancreatic cytokine that can 
regenerate the islet tissue when administered to diabetic mice, 
resulted in improvement in thermal hypoalgesia in the rodent 
model following 2 weeks of treatment.96
inhibition of PARP
Chemical inhibition of PARP offers potential to slow or reverse 
diabetes complications including DPN.63 Weak PARP inhibi-
tors such as nicotinamide can prevent experimental neuropathy 
in diabetic rodents.97 The challenge remains to develop more 
potent inhibitors that can be evaluated in patients.
Angiotensin converting enzyme inhibitors
The role of angiotensin converting enzyme inhibitors in 
DPN is probably due to inhibition of angiotensin II, which 
is a potent vasoconstrictor with pro-inflammatory properties, 
which especially in the absence of NO, promotes thrombosis 
and stimulation of vascular smooth muscle cells and adhe-
sion molecules such as VCAM and intercellular adhesion 
molecules. The efficacy of trandolapril has been studied in 41 
normotensive DPN patients who were randomly assigned to 
active treatment or placebo. Patients on trandolapril showed 
a small but significant improvement in several measures of 
peroneal and sural nerve physiology after 12 months of treat-
ment compared with placebo. Vibration-perception threshold, 
autonomic function, and the neuropathy symptom and deficit 
score, however, showed no improvement in either group.98
Symptomatic treatment
Therapeutic targets to alleviate pain include diabetes-induced 
peripheral and central sensitization (Figures 5 and 6). There 
is no predictor of the response to analgesics dependent on 
the character of the pain, although some believe that burn-
ing pain responds best to antidepressants and shooting pain 
to anticonvulsants. These agents are widely used in clinical 
practice, although not all are supported by adequate prospec-
tive RCTs. It is of great importance to consider individual 
patient comorbidities and drug side-effect profile as many 
agents have dose-related and potentially serious side effects 
(Table 2).
Tricyclic antidepressants
Tricyclic antidepressants (TCAs) inhibit the reuptake of 
norepinephrine and/or serotonin. These agents may act by 
altering the central perception of pain or may antagonize 
the NMDA receptors in the dorsal horn that mediates 
  hyperalgesia and allodynia.99 In a placebo-controlled, 
  double-blind, randomized, cross-over trial comparing 
amitriptyline, desipramine, and fluoxetine with placebo, 
the average effective dose, titrated over 6 weeks to achieve 
control of symptoms, was 111 mg/day for desipramine, 
105 mg/day for amitriptyline, and 40 mg/day for fluoxetine. 
Both TCAs were equally effective and superior to fluoxetine 
or placebo. The beneficial effect was seen within 2 weeks 
and continued to increase at 6 weeks. The clinical response 
and tolerability of side effects are the best guides to dose 
titration, as there was no correlation demonstrated with pain 
relief, dosage, or plasma concentration.99,100 TCAs can cause 
prolongation of the QT interval and are contraindicated in 
patients with recent unstable angina, myocardial infarction, 
heart failure, history of ventricular arrhythmias, and signifi-
cant disease of conduction pathway.101 Concern exists about 
Table 2 Oral therapy for diabetic painful neuropathy
Drug class Drug Daily dose  
(mg)
NNT
Tricyclics Amitriptyline 25–150 2.4 (2.0–3.0)
imipramine 25–150 2.4 (2.0–3.0)
SSRis Paroxetine 40 6.8 (3.4–441)
Citalopram 40 6.8 (3.4–441)
Anticonvulsants Gabapentin 900–1800 3.7 (2.4–8.3)
Pregabalin 150–600 3.3 (2.3–5.9)
Carbamazepine 200–400 3.3 (2.0–9.4)
Topiramate Up to 400 3.0 (2.3–4.5)
Opioids Tramadol 50–400 3.4 (2.3–6.4)
Oxycodone 10–120 2.6 
(1.19–4.1)
SNRis Venlaflaxine 150–200 5.5 
(3.4–4.14)
Duloxetine 60–120 4.0 (3–9)
Abbreviations:  NNT,  number  needed  to  treat;  SNRis,  selective  serotonin 
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their safety, particularly in patients with cardiovascular 
autonomic neuropathy.
Selective serotonin reuptake inhibitors
Selective serotonin reuptake inhibitors (SSRIs) inhibit 
presynaptic reuptake of serotonin but not norepinephrine 
and lack postsynaptic receptor blocking effects. These agents 
can be considered in patients who cannot tolerate TCAs. 
  However, they should be used with caution, especially with 
aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), 
as a case-control study showed moderately increased risk of 
upper gastrointestinal bleeding.99
In a randomized, double-blind, crossover study, parox-
etine 40 mg/day significantly reduced neuropathic symptoms 
compared to placebo but was less effective than imipramine.102 
Paroxetine was also shown to be effective in relieving both 
steady and lancinating type of pain and the therapeutic effect 
was seen within 1 week. The number needed to treat (NNT) 
to achieve .50% pain relief was 6.8 (3.4–441) and was not 
significant. Citalopram but not fluoxetine has been reported 
to have beneficial effects on pain relief.99,103
Selective serotonin norepinephrine 
reuptake inhibitors
Selective serotonin norepinephrine reuptake inhibitors 
(SNRIs) such as duloxetine and venlafaxine have been shown 
to be effective in relieving neuropathic pain by increasing 
the synaptic availability of 5-HT and norepinephrine in the 
descending pathways that inhibit pain impulses. The efficacy 
and safety has been established in three 12-week randomized, 
blinded, controlled trials involving 1102 subjects. Duloxetine, 
60 mg or 120 mg daily, effectively reduced pain intensity 
(47% and 48% vs 29% with placebo).103–110 Duloxetine has 
a rapid onset of action with a reduction in pain scores within 
24 hours with effects persisting for the duration of the study. 
It was effective at relieving pain at night. The medication 
was, in general, well-tolerated with only 20% discontinua-
tion due to side effects. The most common side effects were 
nausea, somnolence, dizziness, decreased appetite, and 
constipation. Duloxetine is not associated with weight gain 
but may cause a slight increase in fasting blood glucose.90 
Duloxetine is licensed for treatment of neuropathy at a dose 
of 60 mg/day.109
The efficacy of venlaflaxine extended release has been 
assessed in a 6-week multicenter, double-blind RCT involv-
ing 244 patients with DPN. Venlaflaxine was associated 
with significant benefit in the primary outcome measures 
of pain intensity and pain relief compared to placebo.   
The most significant improvement in pain score occurred 
with higher dose of venlaflaxine, 50% on 150–225 mg, and 
32% on 75 mg vs 27% on placebo. The effect was attrib-
uted to a neuropathic rather than an antidepressant action 
since patients with depression were excluded. Nausea, 
somnolence, and myalgia were common side effects. Some 
patients on venlaflaxine had significant cardiac rhythm 
abnormalities.111
Anticonvulsants
Anticonvulsants have traditionally been utilized for the 
treatment of painful diabetic neuropathy. Older anticon-
vulsants such as carbamazepine are still useful in treating 
neuropathic pain but have been replaced by newer agents 
such as gabapentin and pregabalin, which have better efficacy 
and safety profile.112,113
Gabapentin is structurally related to aminobutyric acid, 
a neurotransmitter, involved in modulation of pain signals. 
Gabapentin binds to α2-δ subunit of voltage-activated cal-
cium channels on the presynaptic neurone and reduces neu-
rotransmitter release.112,113 In three randomized, double-blind 
studies, gabapentin was shown not only to improve painful 
neuropathy but also has an additional benefit of improving 
sleep.114–116 In an 8-week multicenter dose escalation trial, 
60% of patients treated with gabapentin had moderate pain 
relief compared to 33% on placebo. Of the 165 patients, 
67% achieved doses up to 3600 mg per day, 23% of these 
patients experienced adverse events particularly dizziness and 
somnolence. A randomized study comparing gabapentin and 
amitriptyline did not show any difference in efficacy between 
the two drugs.115
Pregabalin is structurally related to gabapentin and 
has a six-fold higher binding affinity for α2-δ subunit 
of voltage-activated calcium channels but has no action 
on GABA or benzodiazepine receptors.117 It inhibits the 
release of   excitatory neurotransmitters including glutamate, 
substance P, and CGRP.118,119 In a pooled analysis of seven 
  randomized clinical trials of 5–13 weeks duration involving 
a total of 1510 patients, pregabalin at varying doses (150, 
300, 600 mg) demonstrated a significant reduction in mean 
pain score. There was better efficacy with higher doses but 
these were associated with increased incidence of side effects. 
Adverse effects included giddiness, tremors, dry mouth, and 
peripheral edema. Pregabalin-treated subjects demonstrated 
greater weight gain but this did not affect diabetes control. 
The conventional starting dose of pregabalin is 75 mg twice 
daily but this can be slowly titrated to 300 mg in divided 
doses over 1 week or more.120,121Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Sodium channel blockers
Carbamazepine has been traditionally used for neuropathic 
pain and the use is limited by its side effects   (dizziness, 
nausea, skin rash, and rare cases of leucopenia) and 
  limited   efficacy data. Studies have shown lamotrigine can 
attenuate the pain of DPN but the data on topiramate is   
equivocal.122–126
Lacosamide is an antiepileptic drug used as adjunctive 
therapy for partial-onset seizures. Studies suggest that lacos-
amide selectively enhances slow inactivation of voltage-gated 
sodium channels and unlike other anticonvulsants it does not 
influence fast sodium channel inactivation. The mechanism of 
action includes interaction with collapsin response   mediator 
protein 2, which plays an important role in regulating micro-
tubule assembly in neurons.99 Lacosamide has been evaluated 
in a number of studies and in an 18-week, Phase III, double-
blind RCT, lacosamide in doses of 200, 400, 600 mg was 
effective at pain relief in DPN. Similarly, in another Phase 
III trial of 400 mg/day of lacosamide there was an improve-
ment in Likert pain score compared to placebo. Most frequent 
adverse events are headache, nausea, and vertigo.127–129
Topical applications
Topical capsaicin cream
Capsaicin is a naturally occurring pungent substance in red 
peppers and causes analgesia through local tissue deple-
tion of substance P, which is considered to be the primary 
neurotransmitter of painful stimuli from the periphery to the 
central nervous system. In randomized, double-blind placebo-
controlled trials in patients with DPN; capsaicin cream has 
been associated with statistically significant improvement in 
symptoms and quality of life. Pooled data analysis of six trials 
involving 656 patients, showed that the relative benefit of topi-
cal capsaicin (0.075%) compared with placebo was 1.4 (95% 
CI: 1.2–1.7) and NNT was 5.7 (4.0–10.0).130 It is recommended 
that the duration of treatment should not be more than 8 weeks, 
although there were no detectable adverse effects on sensory 
function in diabetic patients. However, a study in healthy sub-
jects showed 74% decrease in epidermal nerve fibers as early 
as 3 days, which may be a mechanism of analgesia, thus raising 
caution for its use in insensitive diabetic foot.131
Topical lidocaine
In an open-label trial, the use of 5% lidocaine patches, (up 
to four patches for 18 hours/per day) significantly improved 
pain and quality of life score in 56 subjects with painful 
DPN.132 In another open-label study of 204 patients with 
DPN, the noninferiority of 5% lidocaine patch compared to 
pregabalin was evaluated. Pain response rate was comparable 
between the two treatment groups and lidocaine showed 
greater improvements in quality of life and had fewer side 
effects.132–134 Lidocaine patches are often utilized in concert 
with other analgesic agents.
Opioids
Opioid receptors are distributed throughout the nervous system 
and are involved in pain transmission and control, including 
primary afferent neurons, spinal cord, midbrain, and thalamus. 
Opioids produce effects on neurons by interacting with recep-
tors located on neuronal cell membranes. The action of opioids 
at the presynaptic nerve terminal is to prevent neurotransmitter 
release and they exhibit inhibitory effects at the postsynaptic 
neuron. Tramadol acts directly via opioid receptors and may 
have an effect on postsynaptic neurons apart from acting 
indirectly via monoaminergic receptor systems. The efficacy 
of tramadol has been studied in a 6-week multicenter trial, 
which included 131 patients with painful DPN. There was 44% 
pain relief in the tramadol treated group compared to 12% on 
placebo. Common side effects are nausea and constipation.135 
Stronger opioids such as controlled release oxycodone in doses 
of 10 to 60 mg appear to be effective and safe in the treatment 
of DPN based on data from two randomized clinical trials. 
Opioids are a useful adjuvant to the treatment of painful DPN 
along with antidepressants.136,137
Other agents
Several other approaches have been evaluated to relieve 
pain in DPN.
Topical agents
Among the topical agents, isosorbide nitrate spray has shown 
promising results in a placebo-controlled pilot study of 22 
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DPN patients, which elicited a reduction in overall neuro-
pathic pain and burning sensation.138 Similar results were also 
obtained by the use of glyceryl trinitrate patches in 18 patients 
with DPN with 44% reporting a reduction in pain.139
The combination of 4% amitriptyline and 2% ketamine 
  (EpiCept NP-1) is being evaluated in Phase IIB study. 
A borderline significant reduction in pain intensity has been 
demonstrated.140 Topical clonidine (0.1% gel) has been 
  evaluated in a Phase II, double-blind RCT in 166 subjects 
with DPN. A 30% reduction in pain was achieved in 47.2% 
of study subjects using the gel compound compared to 29.3% 
on placebo.140
Taurine
Taurine is an antioxidant with effects on neuronal calcium 
signaling which resembles pregabalin in diabetic rodent 
  models.141 Taurine treatment has been shown to improve 
nerve blood flow and electrophysiological parameters and 
exhibit analgesic properties. A Phase II clinical trial utilizing 
a dose of 3 g/day in subjects with DPN is ongoing.
Acetyl-L-carnitine
Acetyl-L-carnitine (ALC), the acetylated ester of the amino 
acid L-carnitine, has been studied in patients with DPN. 
ALC therapy has been associated with significant improve-
ment in pain scores in one of the two identically designed 
randomized, placebo-controlled trials in patients with DPN Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 3 Newer agents for diabetic peripheral neuropathy
Compound Indication Stage of development MOA
Tectin DN
Post-op pain
Post-herpetic
Cancer related pain
Preclinical Sodium channel antagonist
Amitriptyline + ketamine DN
Post-herpetic
Phase ii TCA, SNRi, NMDA antagonist
Clonidine, topical DN Phase ii Alpha 2 adrenoreceptor agonist
Coleneuramide DN Phase ii NGF modulator
indantadol DN
Post-op pain
Phase ii NMDA antagonist and MAO inhibitor
Radiprodil DN Phase ii NMDA 2B receptor antagonist
SB-509 DN
PvD
Phase ii Gene therapy veGF
Acetyl L- carnitine DN Phase iii Antioxidant and affects Na/K ATPase, NO, PGN
Fidarestat DN Phase iii AR inhibitor
Lacosamide DN
epilepsy
Fibromyalgia
Phase iii enhances the inactivation of slow voltage-
dependent NA channels.
Memantine HCL DN Phase iii NMDA antagonist
Nabiximols DN
MS
Cancer pain
Phase iii Cannabinoid receptor 1 agonist
Ranirestat DN Phase iii AR inhibitor
Ruoxistaurin mesylate DN
DR
DNeph
Phase iii PKC inhibitor
Tapentadol, eR DN
Post-op pain
Phase iii Dual mu-opioid receptor agonist and 
norepinephrine reuptake inhibitor
Abbreviations: AR, aldose reductase; DN, diabetic neuropathy; DR, diabetic retinopathy; DNeph, diabetic nephropathy; MAO, mono amine oxidase; MOA, mechanism 
of action; MS, multiple sclerosis; NGF, nerve growth factor; NMDA, N-methyl-D-aspartate; NO, nitric oxide; PGN, prostaglandin; PKC, protein kinase C; PvD, peripheral 
vascular disease; SNRi, serotonin noradrenaline reuptake inhibitor; TCA, tricyclic antidepressant; veGF, vascular endothelial growth factor.
at doses of 1000 mg three times daily. This benefit needs to 
be confirmed in future studies.142,143
Nonsteroidal anti-inflammatories
NSAIDs may be effective in DPN patients with underlying 
musculoskeletal or joint abnormalities by modulating the 
nociceptive and inflammatory pain pathways. Ibuprofen at 
a dose of 600 mg four times daily and sulindac at a dose of 
200 mg twice daily can provide pain relief in DPN.144
Failure to respond to pharmacological agents may require 
referral to a pain clinic at which specialized techniques 
such as transcutaneous electrical nerve stimulation (TENS), 
percutaneous electrical nerve stimulation, or spinal cord 
electrostimulation should be considered.
Management of focal neuropathies
Few systematic studies have addressed the optimal 
approach to the management of most focal neuropathies. 
Diabetic amyotrophic may benefit from use of steroid 
and   immunoglobulins. There are also anecdotal reports of 
insulin being beneficial.43–45 The management for foot drop 
secondary to peroneal nerve damage is supportive including 
splints. Surgical decompression can be of value in median 
nerve entrapment and has been utilized in other compression 
focal neuropathies.145
Treatment algorithm based  
on present evidence
The first-line treatments based on clinical trial evidence are an 
SNRI, an α-2-δ agonist, or TCA. Thus, duloxetine, pregabalin, 
or amitriptyline would be the drugs of choice as initial therapy 
after consideration of factors such as comorbidities and cost. 
Duloxetine is contraindicated in patients with liver disease 
and pregabalin should be avoided in those with edema. Car-
diovascular disease or cardiac autonomic neuropathy (CAN) 
may preclude the use of amitriptyline. If pain control is not 
adequate, then a combination of first-line therapies could be 
considered before utilizing opioids16 (Figure 4).
Conclusions
DPN remains a common and disabling complication of dia-
betes. The initial treatment of DPN should focus upon the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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identification of risk factors and intensification of metabolic 
control, the implementation of a diabetic foot care program 
in subjects with insensitivity, and the provision of adequate 
pain or symptom relief to improve quality of life. In some 
patients, negative symptoms (ie, numbness or loss of func-
tion) are as disabling as positive symptoms such as pain and 
are perhaps more challenging to treat. Patient education is the 
key and pathophysiology of the disease should be explained 
and a treatment plan agreed upon. The psychological con-
sequences of DPN should be sought and treatment offered. 
Symptoms that interfere with sleep are particularly disabling. 
Therapeutic strategies should be individualized taking into 
consideration underlying patient comorbidities. It is also 
important not to ignore multifactorial risk interventions such 
as weight reduction and smoking cessation along with blood 
pressure and lipid control. Improving patient mobility and the 
instigation of exercise regimens can be helpful in reducing 
symptoms. Newer techniques such as magnetic resonance 
imaging, IENFD, and corneal confocal microscopy are 
offering new insights into the pathogenesis of pain and small 
sensory fiber damage in DPN and directing the development 
of therapeutic agents (Table 3). Despite the relative lack of 
success of interventional agents to slow or reverse established 
DPN, approaches such as gene therapy to promote neurotro-
phism and the targeted delivery of antioxidant therapy may 
in the future offer the best potential to reverse this common 
and disabling complication of diabetes.
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